Get the Stockscreener App
2.735
0.18%
-0.005
Mannkind Corp stock is traded at $2.735, with a volume of 2.24M.
It is down -0.18% in the last 24 hours and down -1.26% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$2.74
Open:
$2.71
24h Volume:
2.24M
Relative Volume:
0.40
Market Cap:
$844.56M
Revenue:
$348.97M
Net Income/Loss:
$5.86M
P/E Ratio:
162.80
EPS:
0.0168
Net Cash Flow:
$13.69M
1W Performance:
+4.79%
1M Performance:
-1.26%
6M Performance:
-47.71%
1Y Performance:
-41.06%
1-Day Range:
$2.67
$2.77
1-Week Range:
$2.55
$2.77
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
2.735 | 846.10M | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
444.50 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.09 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
843.45 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
336.61 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.30 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MNKD Maintains Rating by Mizuho -- Price Target Lowered to $8.00 - GuruFocus
Leerink reiterates Outperform on MannKind stock, sees overreaction - Investing.com
Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com - Investing.com UK
Risk Check: Is MannKind Corporation in a bullish channel2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart
MannKind (NASDAQ: MNKD) details 2026 virtual meeting, board elections and pay vote - Stock Titan
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
Q4 2025 MannKind Corp Earnings Call Transcript - GuruFocus
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Q2 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Truist reiterates MannKind stock rating on partner trial data By Investing.com - Investing.com India
Truist reiterates MannKind stock rating on partner trial data - Investing.com
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? - Insider Monkey
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A - Stock Titan
MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan
MannKind (MNKD) awards performance RSUs and stock options to officer - Stock Titan
Setup Watch: Is now the right time to enter MannKind CorporationTrend Reversal & Smart Allocation Stock Reports - baoquankhu1.vn
How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance
Chart Watch: Whats the beta of MannKind Corporation stockMarket Risk Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure - Markets Mojo
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss - AD HOC NEWS
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's What Happened - MarketBeat
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
MannKind Corp. Stock Plummets to New 52-Week Low of $3.29 - Markets Mojo
Portfolio Update: Is MannKind Corporation in a bullish channel2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
(MNKD.O) | Stock Price & Latest News - Reuters
MannKind Corp Stock (ISIN: US5638651064) Faces Pressure Amid Biotech Selloff and Analyst Cuts - AD HOC NEWS
MannKind (NASDAQ:MNKD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Why MannKind Needs Your Attention - RTTNews
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
Insider Stock Purchases: March 11, 2026 | FOUR Stock News - Quiver Quantitative
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ: MNKD) CEO purchases 100,000 shares in market trade - Stock Titan
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - The Manila Times
MannKind presents Afrezza data at diabetes conference - Investing.com
MannKind Corporation to Present Data on Inhaled Insulin Afrezza at ATTD 2026 Conference - Quiver Quantitative
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
Vanguard Group Inc. Has $94.68 Million Holdings in MannKind Corporation $MNKD - MarketBeat
MannKind settles $36.3M convertible notes with cash, shares By Investing.com - Investing.com Canada
MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Re - GuruFocus
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
MannKind closes note deal with $35.5M cash and 569,023 shares - Stock Titan
Wedbush Lowers Price Target for MannKind (MNKD) While Maintainin - GuruFocus
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wedbush - MarketBeat
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tross Stuart A | Chief People & Workpl Officer |
Jan 08 '26 |
Sale |
6.33 |
47,006 |
297,548 |
985,007 |
2.64%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):